PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY

EUROPEAN COMMISSION

Prior notification of a concentration

(Case M.10629 – CSL / VIFOR PHARMA)

(Text with EEA relevance)

(2022/C 180/05)

1. On 26 April 2022, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 [1].

This notification concerns the following undertakings:

— CSL Behring AG ('CSL Behring', Australia), controlled by CSL Limited ('CSL', Australia), a public company listed on the Australian Security Exchange,

— Vifor Pharma Limited ('Vifor Pharma', Switzerland), a public company listed on the Swiss Stock Exchange.

CSL will acquire within the meaning of Article 3(1)(b) of the Merger Regulation sole control over Vifor Pharma.

The concentration is accomplished by way of public bid announced by CSL Limited on 14 December 2021.

2. The business activities of the undertakings concerned are the following:

— CSL is a biotechnology company with a portfolio of medicines, including those that treat hemophilia and immune deficiencies (through CSL Behring), as well as vaccines to prevent influenza (through Seqirus), and through CSL Plasma, a division of CSL Behring, it operates a plasma collection network,

— Vifor Pharma is active worldwide in the development, manufacturing, and marketing of pharmaceutical products for the treatment of iron deficiency, nephrology (kidney care), and cardio-renal therapies.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.10629 – CSL / VIFOR PHARMA

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

European Commission
Directorate-General for Competition
Merger Registry
1049 Bruxelles/Brussel
BELGIQUE/BELGIË

[1] OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation').